Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.

No Thumbnail Available

Date

2021-11-24

Authors

Gallego-Duran, Rocio
Montero-Vallejo, Rocio
Maya-Miles, Douglas
Lucena, Ana
Martin, Franz
Ampuero, Javier
Romero-Gomez, Manuel

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Frontiers Research Foundation
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi-organ involvement. This entity has displaced viral hepatitis as the main cause of severe forms of hepatic diseases, although the onset and transition of MAFLD stages still remains unclear. Nevertheless, innate and adaptive immune responses seem to play an essential role in the establishment and further progression of this disease. The immune system is responsible of safeguard and preserves organs and systems function, and might be altered under different stimuli. Thus, the liver suffers from metabolic and immune changes leading to different injuries and loss of function. It has been stablished that cell-cell crosstalk is a key process in the hepatic homeostasis maintenance. There is mounting evidence suggesting that MAFLD pathogenesis is determined by a complex interaction of environmental, genetic and host factors that leads to a full plethora of outcomes. Therefore, herein we will revisit and discuss the interplay between immune mechanisms and MAFLD, highlighting the potential role of immunological markers in an attempt to clarify its relationship.

Description

MeSH Terms

Animals
Humans
Non-alcoholic Fatty Liver Disease

DeCS Terms

Enfermedad
Hígado
Células
Contabilidad
Sistema inmunológico
Hígado graso
Heridas y lesiones
Inmunidad

CIE Terms

Keywords

NAFLD, NASH, biomarkers, fibrosis, immunology

Citation

Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, et al. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Front Immunol. 2021 Nov 24;12:667354.